Gluconic Acid

Gluconic Acid

SCHEMBL193661

O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 1.00
LMNA P02545 2/20 0.67
USP2 O75604 1/20 0.60
SLCO1B1 Q9Y6L6 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 1/20 0.55
TSHR P16473 2/20 0.52
CYP2C9 P11712 1/20 0.52
OR51E2 Q9H255 1/20 0.43
KDM4E B2RXH2 2/20 0.41
PGD P52209 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconic Acid SCHEMBL13056936 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL16609838 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL16592174 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL15339348 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL8462892 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL16609840 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL19257183 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL14617612 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL21778048 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Mucic Acid SCHEMBL17164506 1.00 PDE4A (1.00) PDE4ALMNAUSP2SLCO1B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2742 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630578-B2 Methods for the production of calcium, magnesium, and zinc salts of sugar acids DFI USA, LLC (US) 2026-05-19 US claimed
CN-122036704-A Free base crystal form or acid salt of biaryl compound, preparation method and medical application thereof 江苏豪森药业集团有限公司 2026-05-15 CN claimed
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-12624276-B2 Compositions and methods for the dissolution of iron sulfide SOLUGEN, INC. (US) 2026-05-12 US claimed
US-12624050-B2 Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2026-05-12 US claimed
US-12624311-B2 Multifunctional cleaner comprising a mixture of biochelants and methods of making and using same SOLUGEN, INC. (US) 2026-05-12 US claimed
EP-4721739-A1 CSF-1R INHIBITOR PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2026-04-08 EP claimed
US-12566161-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-03 US claimed
CN-121586715-A Salt and crystal forms of methionine adenosine transferase 2A heterocyclic inhibitor and preparation method thereof 南京正大天晴制药有限公司 2026-02-27 CN claimed
WO-2026044024-A1 COMPOSITIONS COMPRISING COMBINATIONS OF PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF AMYLIN ANALOG, AND USES THEREOF I2O THERAPEUTICS, INC. (US) 2026-02-26 WO claimed
EP-0273202-B1 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. SCOTT EUGENE J VAN (US) 1995-06-21 EP claimed
WO-1992018116-A1 COMPOSITIONS COMPRISING 2-HYDROXYCARBOXYLIC ACIDS AND RELATED COMPOUNDS, AND METHODS FOR ALLEVIATING SIGNS OF DERMATOLOGICAL AGING YU RUEY J (US) 1992-10-29 WO claimed
EP-0508324-A2 Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging Yu, Ruey J., Dr. (US) 1992-10-14 EP claimed
EP-0142969-B1 MILBEMYCIN 5-CARBONATE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1989-05-31 EP claimed
EP-0276284-A4 METHOD OF THERMALLY PROCESSING FOODSTUFFS. AMERICAN NAT CAN CO (US) 1988-12-01 EP claimed
EP-0276284-A1 METHOD OF THERMALLY PROCESSING FOODSTUFFS AMERICAN NATIONAL CAN COMPANY (US) 1988-08-03 EP claimed
EP-0273202-A2 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. Van Scott, Eugene J., Dr. (US) 1988-07-06 EP claimed
WO-1988000799-A1 METHOD OF THERMALLY PROCESSING FOODSTUFFS AMERICAN NATIONAL CAN COMPANY (US) 1988-02-11 WO claimed
US-4246261-A HYDROXY ACIDS, ESTERS, LACTONES SCOTT EUGENE J VAN 1981-01-20 US claimed
US-3985870-A D-GLUCOHEPTONO-1,4-LACTONE AND CALCIUM COMPOUND ABRASIVE PFANSTIEHL LABORATORIES, INC. (US) 1976-10-12 US claimed